FDA approves Bkemv the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases – Amgen
The FDA approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is approved for the following treatment indications, which are… read more.
